Dasatinib vs imatinib in the treatment of paediatric ALL скачать в хорошем качестве

Dasatinib vs imatinib in the treatment of paediatric ALL

Dr Shuhong Shen speaks to ecancer at the ASH 2019 meeting in Orlando about updated results from a study treating paediatric Acute Lymphoblastic Leukaemia. This open-label phase III randomised study was conducted at 20 hospitals in China. Of the 225 patients with the diagnosis, 35 declined and 1 died before treatment. Intensive chemotherapy including dasatinib at 80 mg/m2 per day yielded superior results in the treatment of Philadelphia chromosome-positive ALL compared to imatinib at 300 mg/m2 per day and provided excellent control of central-nervous-system leukaemia without the use of prophylactic cranial irradiation. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php